Biotech Analyst Goonewardene discusses Gastrointestinal Cancer (relevant companies EXEL, MRUS, JNJ, RVMD) on an Analyst/Industry conference call to be held on July 10. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $53 from $47 at H.C. Wainwright
- Exelixis’s Promising STELLAR-303 Trial Results Lead to Buy Rating and Increased Approval Probability
- NuScale, Hims & Hers, Snowflake, Advance Auto Parts, Exelixis: Trending by Analysts
- Exelixis price target raised to $50 from $42 at Jefferies
- Lyft upgraded, Block assumed: Wall Street’s top analyst calls